PFE Stock Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Pfizer Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.23 |
| 52 Week High | US$31.54 |
| 52 Week Low | US$24.48 |
| Beta | 0.59 |
| 1 Month Change | -3.85% |
| 3 Month Change | -13.48% |
| 1 Year Change | -5.36% |
| 3 Year Change | -57.09% |
| 5 Year Change | -35.12% |
| Change since IPO | 5,468.01% |
Recent News & Updates
Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns
Dec 11Pfizer: Too Cheap To Ignore
Dec 05Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks
Nov 21Recent updates
Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns
Dec 11Pfizer: Too Cheap To Ignore
Dec 05Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks
Nov 21Big Pharma Reckoning Looms With RFK Jr. Eyeing Pfizer
Nov 15Some Investors May Be Willing To Look Past Pfizer's (NYSE:PFE) Soft Earnings
Nov 13
Pfizer: Discounted For A Reason - But Dividend Story Remains Rich
Nov 08Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 01Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed
Oct 29Pfizer: Activists Clouding A Promising Picture
Oct 21Pfizer: A Strong Product Pipeline Could Lead To Significant Upside
Oct 08Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'
Oct 01There's Reason For Concern Over Pfizer Inc.'s (NYSE:PFE) Price
Sep 23Pfizer: Undervalued Healthcare Leader Poised For Further Recovery
Sep 23Why Pfizer Investors Should Closely Monitor VAX-31
Sep 05Shareholder Returns
| PFE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.6% | -0.2% |
| 1Y | -5.4% | 9.3% | 28.8% |
Return vs Industry: PFE underperformed the US Pharmaceuticals industry which returned 9.3% over the past year.
Return vs Market: PFE underperformed the US Market which returned 28.8% over the past year.
Price Volatility
| PFE volatility | |
|---|---|
| PFE Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PFE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PFE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1849 | 88,000 | Albert Bourla | www.pfizer.com |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands.
Pfizer Inc. Fundamentals Summary
| PFE fundamental statistics | |
|---|---|
| Market cap | US$144.90b |
| Earnings (TTM) | US$4.27b |
| Revenue (TTM) | US$59.38b |
33.5x
P/E Ratio2.4x
P/S RatioIs PFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PFE income statement (TTM) | |
|---|---|
| Revenue | US$59.38b |
| Cost of Revenue | US$17.94b |
| Gross Profit | US$41.43b |
| Other Expenses | US$37.16b |
| Earnings | US$4.27b |
Last Reported Earnings
Sep 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 69.78% |
| Net Profit Margin | 7.20% |
| Debt/Equity Ratio | 73.4% |
How did PFE perform over the long term?
See historical performance and comparison